Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

NCT03971253 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03971253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Lead sponsor
Astellas Pharma Inc
Phase
Observational
Overall status
Completed
Start date
September 2, 2019
Completion date
May 29, 2026
Enrollment
3,000 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra)